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Abstract
Background: Merkel cell carcinoma is a rare, very aggressive neuroectodermal tumor of the skin. It is typically
located on sun-exposed skin and frequently found in white men aged between 70 and 80 years.
Case presentation: We report a case of a 58-year-old black woman diagnosed with Merkel cell carcinoma of
the posterior face of the right elbow. She had biopsy excision and was lost to follow-up. Four months later,
she presented with recurrent disease on the inferior third of the right arm with three ipsilateral axillary lymph
node metastases. Amputation of the right arm and ipsilateral axillary lymph node dissection were performed,
followed by adjuvant radiotherapy. Six months later, the patient died as a result of respiratory failure caused
by lung metastasis. To the best of our knowledge, no specific studies have been done comparing the course
and the characteristics of Merkel cell carcinoma in white and black populations, and no similar case has been
reported in the literature.
Conclusions: The Merkel cell carcinoma is very rare in black people. As described elsewhere in the literature,
our patient had a poor outcome despite radical management. To date, to the best of our knowledge, there
has been no comparison of the prognosis of this tumor in white and black populations.
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Background
Merkel cell carcinoma (MCC) is a rare and very aggres-
sive neuroendocrine tumor of the skin [1]. It affects
adults with light skin types in the seventh decade of life
and has a high rate of local recurrence and regional
lymph node metastasis [2]. MCC was first described in
1972 by Toker [3]. It seems to arise from the basal layer
of the epidermis where specific cells—the Merkel cells—are
located [4]. This hypothesis is controversial, and recent
observations suggest that these tumors originate from
an immature totipotential dermal stem cell that
acquires neuroendocrine features during malignant
transformation [5].
We report a rare case of an epidemiological presentation
of MCC occurring in the right elbow of a black woman.
We also try to show through this case if there are
differences in prognosis between MCC occurring in white
and black people.
Case presentation
A 58-year-old African black woman with a medical
history of diabetes presented to our institute with a
rapidly growing skin lesion that was initially a small,
round, painless nodule on the posterior face of the
right elbow. In a physical examination at the time of
admission, a 50 × 30-mm purple lesion with an ir-
regular surface on the posterior face of the right
elbow and extending to the forearm was found. No
ipsilateral axillary lymph nodes were found. The
patient had stage II disease. A biopsy excision was
performed. The pathological examination showed a
proliferation of round, small cells (Fig. 1a, b). An im-
munohistochemical study using specific staining tech-
niques confirmed the diagnosis of MCC and, more
specifically, cytokeratin 20 (CK20) expression, which
is often evident as a paranuclear globule (Fig. 2);
synaptophysin (Fig. 3); CD99; neuron-specific enolase;
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and negativity of the melanocytic and muscular
markers. The patient was lost to follow-up and
consulted us 4 months later. The physical examin-
ation done at that time revealed a large inflammatory
lesion of 100 × 50 mm on the third inferior side of
the right arm with three ipsilateral axillary lymph
nodes. A magnetic resonance imaging (MRI) scan of
the right arm showed a process of the soft parts of
103 × 63 × 50 mm with three metastatic ipsilateral
axillary lymph nodes (Fig. 4).
A biopsy of one of the axillary lymph nodes con-
firmed the diagnosis of MCC. Computed tomography
(CT) of the chest, abdomen, and pelvis showed no
distant metastasis. The treatment planning consisted
of surgical amputation of the right arm with ipsilat-
eral axillary lymph node dissection. A histopathologic
examination revealed negative surgical margins. The
margins were found to be microscopically uninvolved
by carcinoma, with the closest margin at 4 mm
(deep margin). Of 31 excised lymph nodes, 13 that
were metastatic with capsular rupture were found.
The patient was referred to our radiation therapy de-
partment. At that admission, the examination revealed a
clean amputation stump and no axillary lymphadenop-
athy, but the patient had a fixed mass in the right axilla.
A CT scan showed a process in the right axillary region
extending to the right subscapularis fossa (Fig. 5). No
surgical treatment was possible. A decision was made to
perform radiation therapy of the right axillary and
subscapularis regions. The total dose was 66 Gy with a
conventional fractionation of 2 Gy per fraction in 33
sessions, 5 days per week, in the right axillary and sub-
scapular areas in two oblique fields: anterior right and
posterior left fields. The patient had grade 2 radioderma-
titis as the only acute toxicity of radiotherapy.
Six months later, the patient presented with dyspnea
caused by lung metastasis, and she died 1 month after-
ward as a result of respiratory failure.
Discussion
MCCs are rare tumors of the skin. According to National
Cancer Institute Surveillance, Epidemiology, and End
Results Program data, the estimated annual incidence in
2006 was 0.6 per 100,000 persons [6]. In Australia and
New Zealand, higher incidence rates are reported [7].
These tumors occur mostly in the white population (94%)
Fig. 1 a Cutaneous neuroendocrine carcinoma. Typical low-power
view of a small blue-cell tumor (hematoxylin and eosin stain, original
magnification ×40). b Microphotograph showing pale-staining, small,
round cell proliferation containing tiny nucleoli (hematoxylin and
eosin stain, original magnification ×40)
Fig. 2 High-power view of the tumor showing strong expression of
cytokeratin 20 (original magnification ×40)
Fig. 3 High-power view of the tumor showing strong expression of
synaptophysin (original magnification ×40)
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[8, 9]. Males develop MCC more often than females, with
incidence rates of 0.41 and 0.18 cases per 100,000 person-
years, respectively [6]. MCC is typically seen in the elderly,
with mean ages at diagnosis of 74 years for men and 76
years for women [6]. Our patient was a 58-year-old
woman.
MCCs often occur on sun-exposed regions of the skin
[8, 9]. The etiology is largely uncertain, though there is
some evidence that ultraviolet radiation and immune
system depression are important risk factors. More re-
cently, some studies have shown the role of the Merkel
cell polyomavirus (MCV) group in the development of
this tumor [8, 10]. MCV has been isolated in up to 80%
of the MCC tissue analyzed [11].
MCC presents as a painless, purple lump on the skin,
sometimes ulcerated. It can be multifocal [1]. The head
and neck are the most common primary sites (48%),
followed by the upper limbs (19%), lower limbs (16%),
and trunk (11%) [12]. Most patients (73%) present with
localized disease (stages I–II); 23% have regional disease
(stage III), and 4% have stage IV metastatic disease [12].
The histological presentation of MCC is small, round,
blue-cell tumors and need to be distinguished from
lymphoma, melanoma, sarcoma, and metastatic skin de-
posits from other neuroendocrine carcinomas, in par-
ticular small cell lung carcinoma. Immunohistochemical
study characteristics of neuroendocrine carcinoma of the
skin is low-molecular-weight (CAM 5.2) keratin, and
more specifically CK20 expression, which is often evi-
dent by paranuclear immunostaining [13]. CK7 is char-
acteristically negative in MCC and may be positive in
small cell lung carcinoma [13]. Neuroendocrine markers
(neurofilament protein, chromogranin, and synaptophy-
sin) are frequently expressed in MCC tumors [14]. The
tumor cells are negative for leukocyte common antigen,
HMB-45, Melan-A, desmin, and myogenin. A protocol
of examination of specimens from patients with MCC
has been developed to assist pathologists in providing
clinically relevant information [15, 16].
Common sites of MCC metastasis include distant
lymph nodes (60%), distant skin (30%), lung (23%),
central nervous system (60%), and bone (15%) [12]. CT
and MRI scans are obtained to evaluate MCC and for
treatment planning, but there is no accepted imaging al-
gorithm [8]. Recently, however, some studies have shown
that fluorodeoxyglucose-positron emission tomography
is a highly sensitive modality for MCC evaluation before
and after treatment [5].
The standard treatment of the primary tumor remains
surgical. Removal by wide local excision is typical, with
some surgeons also using Mohs micrographic surgery to
ensure adequate clear margins at excision [17]. Lymph
node dissection and primary nodal radiotherapy are op-
tions for treating clinically node-negative disease. For
clinically palpable regional disease, lymph node dissec-
tion is recommended with consideration of adjuvant ra-
diation therapy. In recent studies, the role of sentinel
lymph node biopsy in guiding adjuvant treatment has
been established [18]. Adjuvant radiotherapy doses
ranged from 45 to 66 Gy, depending on the techniques
used and the presence of microscopic or gross disease
after surgery. The role of neoadjuvant and adjuvant
chemotherapy is not clear and should be analyzed in
more studies [8].
Prognostic factors are primary tumor size up to 2 cm
and a high mitotic index, which may contribute to a
higher risk of locoregional recurrence [19, 20]. An in-
creasing number of metastatic nodes is associated with
Fig. 5 Computed tomography slice showing a mass in the right
axillary and subscapularis regions
Fig. 4 Contrast-enhanced, T1-weighted axial magnetic resonance
imaging scan showing the process of the soft parts on the right arm
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significantly worse overall survival [8, 21]. Five-year sur-
vival is 57% for localized disease, 39% for regional dis-
ease, and 18% for metastatic disease [19, 22]. Recurrence
rates of MCC are high, with most occurring within 2
years (often earlier) and increasing with higher stage at
presentation [23, 24].
In our patient, the tumor size was up to 2 cm, and
she presented with locoregional recurrence very early
(4 months). She died after lung metastasis only 6
months after the end of treatment. To the best of our
knowledge, there are no studies in the literature in
which researchers analyzed the impact of skin color
and geographic or ethnic origin on the prognosis of
MCC. As in the other nonmelanoma skin cancers
(basal and squamous cell carcinoma), routine skin scan-
ning and dermatological examination should be done in
the elderly population to provide early diagnosis and
therapeutic care [25].
Conclusions
MCC presents rarely in dark-skinned people, which sug-
gests a protective role of their skin pigmentation. As seen
in our patient and as reported in the literature, MCC has
a poor outcome. However, more studies should be done
to analyze the difference in prognosis between light- and
dark-skinned populations. The high rate of local and
distant recurrence of MCC despite radical management
and a multidisciplinary approach deserve more research
on the role of systemic treatment.
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